Olav D.
- Country
- Norway
- Department
- Department of Oncology
Research Overview
- Phase III Randomized Double-Blind Study of Rilvegostomig Plus Chemotherapy in Adjuvant Treatment of Resected Biliary Tract Adenocarcinoma
- Phase 1/2 Evaluation of Synthetic Cannabinoid ART27.13 for Cancer Anorexia and Weight Loss in Oncology Patients
- A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
Data & Insights
Has run more than one trial at 16 of 104 partner sites.
Specializations
Hepatobiliary Oncology
The investigator specializes in treating hepatocellular carcinoma (HCC), conducting research in both early-stage and advanced disease settings. Their work encompasses surgical resection outcomes and innovative therapeutic approaches for incurable cases.
- Non-metastatic liver cancer management
- Post-surgical adjuvant therapy
- Combined treatment modalities
Additional focus includes transarterial chemoembolization (TACE) procedures integrated with systemic therapies.
Biliary Tract Cancer
The investigator's expertise extends to biliary tract malignancies, with particular attention to post-surgical treatment strategies. Their research encompasses both intrahepatic and extrahepatic cholangiocarcinoma.
- Curative-intent surgical approaches
- Adjuvant chemotherapy protocols
- Gallbladder cancer treatment
Research focuses on muscle-invasive gallbladder cancer and novel therapeutic combinations.
Supportive Cancer Care
The investigator addresses cancer-related complications, with specific interest in managing cancer anorexia and weight loss. Their work includes evaluation of novel therapeutic compounds for symptom management.
- Weight management in cancer
- Performance status improvement
- Quality of life enhancement
Studies include assessment of synthetic cannabinoids for cancer-related appetite loss.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.